Featured Post from Augusta University

FAST nanotechnology unveiled at Rome Global Congress by AU scientist

The work is the culmination of decades of research for Stephen Hsu, PhD.

Jun 25, 2025

3 min

Stephen Hsu, PhD, a professor at the Dental College of Georgia at Augusta University, unveiled his groundbreaking nanotechnology, known as FAST, during a keynote address at the 8th World Congress on Infectious Diseases in Rome, Italy.


FAST, or Facilitated Self-Assembling Technology, offers a revolutionary way to convert compounds that are difficult to dissolve in water into stable nanoparticles. This innovation could transform drug development, viral infection prevention, hospital hygiene and more.


“FAST takes a completely different approach from traditional nanotechnology,” Hsu explained. “Unlike methods that rely on polymers, metals, surfactants, fat-based carriers or complex engineering processes, FAST allows compounds to self-assemble into nanoparticles with minimal effort. This makes drugs that were once nearly impossible to formulate in water stable, effective and practical for medical and consumer use.”


At the heart of this innovation is EC16, or EGCG-palmitate, a lipid-soluble compound derived from green tea. Known for its antioxidant, anticancer, anti-inflammatory and antimicrobial properties, green tea has long been studied but is challenging to use in clinical settings due to stability issues. FAST overcomes these limitations, transforming EC16 and other hydrophobic compounds into water-friendly nanoparticles.


“You can’t even tell the particles are there,” said Hsu. “They look just like water. I made several different formulations in one afternoon in my lab. It’s that fast and simple.”


CaptionResizeWrap TextRemove


A natural solution to global challenges


Hsu’s work is the culmination of decades of research and a deeply personal journey. He credits green tea with helping him survive illness during his youth in a labor camp in China. Now, he’s turning its natural properties into cutting-edge therapies with the hope of helping more people.


“I’ve been drinking green tea my entire life,” Hsu said. “Now, we’re turning its benefits into medical-grade treatments.”


Supported by over $600,000 in NIH grants, Hsu’s team is developing applications like alcohol-free disinfectants and nasal sprays to prevent respiratory virus infections. One promising product is an EC16-based disinfectant that is natural, non-toxic and highly effective against tough pathogens, like norovirus and C. difficile, a bacterium that can cause severe diarrhea.


“That’s a big deal for schools, hospitals and places like cruise ships, where these infections spread easily,” he said.


CaptionResizeWrap TextRemove


Tackling long COVID and beyond


Among FAST’s most promising applications is a nasal spray developed to prevent or treat long COVID and other respiratory illnesses. The spray, currently undergoing preclinical testing, targets viral entry points in the nasal mucosa, where infections often begin.


“Our goal is to help immunocompromised patients and those with lingering symptoms like brain fog and loss of smell,” Hsu said. “We’ve already seen strong in vitro results against human coronavirus and norovirus.”


In addition to nasal and topical treatments, Hsu’s team has developed oral formulations of EC16 that remain stable through the stomach’s acidic environment, critical for treating gastrointestinal viruses and potentially inflammatory bowel diseases like Crohn’s.


“We found that even without direct contact with the virus, the EC16 nanoparticles taken by mouth can reduce infection,” Hsu explained. “That’s a major step forward in treatment of digestive tract viral infections.”


A platform for the future of medicine


CaptionResizeWrap TextRemove


FAST isn’t limited to green tea compounds. Hsu’s method can transform a wide range of hydrophobic compounds like cannabidiol, ivermectin, quercetin, procyanidin and retinoic acid, as well as hundreds of existing drugs, into nanoparticle suspensions that are stable and water-friendly.




This has huge implications,” said Hsu. “Up to 90% of new drug candidates have poor water solubility and low bioavailability, which limits their effectiveness. With FAST, we can change that.”


His lab is already exploring applications in Alzheimer’s research, cancer therapy, oral health and even anti-biofilm coatings to prevent hospital infections. These products, along with the nasal spray, are expected to hit the market this fall.


Hsu is currently finalizing publications and preparing patent filings to protect and expand the reach of FAST. While optimistic, he remains cautious.


“The results so far are phenomenal. FAST could be a new chapter in how we fight disease and deliver medicine,” Hsu said.


Looking to know more about FAST nanotechnology and the research happening at Augusta University?



To connect with Dr. Stephen Hsu - simply contact AU's External Communications Team mediarelations@augusta.edu to arrange an interview today. 

You might also like...

Check out some other posts from Augusta University

2 min

Fueling the Future of Cancer Immunotherapy: Gang Zhou’s Research Takes a Major Step Forward

Cancer immunotherapy has transformed how clinicians approach the treatment of certain blood cancers, but major limitations remain — especially when it comes to sustaining strong, long-lasting immune responses. Gang Zhou, PhD, a leading cancer immunologist at Augusta University’s Georgia Cancer Center and the Immunology Center of Georgia, is tackling these challenges head-on. Zhou’s work focuses on how T cells behave inside the body and how their performance can be enhanced to improve patient outcomes. His lab studies the forces that strengthen or weaken T cell responses, including their functional status, their ability to self-renew and the environmental pressures they face inside tumors. This deep understanding positions him as a key figure in the effort to advance next-generation immunotherapies. Recently, Zhou and his research team were awarded the first Ignite Grant from the Immunology Center of Georgia — a seed program designed to support bold, high-impact translational ideas. Their funded project aims to make CAR-T therapy more effective. CAR-T is a type of immunotherapy in which a patient’s own T cells are genetically modified to recognize and attack cancer cells. While this approach has revolutionized the treatment of certain blood cancers, it still faces obstacles such as limited cell persistence and reduced strength over time. “Our ultimate goal is to engineer T cells that not only survive longer but also remain highly functional, giving patients more durable protection against their disease.” Zhou’s team is addressing this issue by studying how a modified form of STAT5, a transcription factor that plays a key role in T cell survival and function, may help engineered T cells last longer and perform better. The ultimate goal is to create CAR-T therapies that maintain potency, withstand the harsh tumor microenvironment, and offer durable results for patients. The Ignite Grant recognizes not only the promise of this specific project, but also Zhou’s broader expertise in understanding how T cells can be guided, supported, and strengthened to fight cancer more effectively. His research contributes to a growing wave of scientific innovation aimed at improving immunotherapy outcomes for patients with both blood cancers and, potentially, solid tumors — an area where current treatments face significant barriers. As immunotherapy continues to evolve, the work led by Gang Zhou stands as a compelling example of how foundational science, translational research, and clinical ambition can work together to push the field forward. To connect with Dr. Gang Zhou - simply contact AU's External Communications Team mediarelations@augusta.edu to arrange an interview today.

3 min

MCG scientists investigate arthritis drug’s impact on Alzheimer’s disease

According to the Alzheimer’s Association, more than 7 million Americans are living with Alzheimer’s disease, and one in nine of those people is 65 or older. Although that number is expected to grow, researchers at the Medical College of Georgia at Augusta University are making progress on studies that could turn into life-saving treatments. Qin Wang, MD, PhD, professor in the Department of Neuroscience and Regenerative Medicine at MCG and Georgia Research Alliance Eminent Scholar in neuropharmacology, recently published a study titled “The PKCι‑β‑arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease,” in Molecular Degeneration, a leading journal in neurodegeneration. In the study, Wang and her team explored how certain proteins and enzymes interact in the brains of Alzheimer’s patients. Key players include the SORL1 gene, the PKCι enzyme and proteins SORLA, β‑arrestin2 and amyloid. SORL1 encodes SORLA, which helps regulate amyloid. Amyloid can form plaque in the brain, contributing to Alzheimer’s. People with the disease often have lower SORLA levels, which amplifies plaque production. “The goal is to increase SORLA levels in patients with AD. If we can boost it up, that would be great,” Wang said. “But if you want to know how to boost it up, you have to know how it is degraded, so that’s what our work is about – we’re trying to understand how its stability is regulated.” Wang’s research team found that PKCι can add a phosphate group to SORLA, which helps SORLA interact with β‑arrestin2. The PKCι‑β‑arrestin2 axis leads to SORLA degradation, reducing its levels and allowing amyloid plaques to grow unchecked, thereby worsening the disease condition. They discovered this by using biochemical methods and a mass spectrometer managed by Wenbo Zhi, PhD, at the Proteomics and Mass Spectrometry core lab at AU. “We conducted biochemical studies and found that SORLA can be phosphorylated. We identified the phosphorylation site and the interacting enzymes,” Wang explained. “Using the mass spectrometer with PKCι, we saw increased phosphorylation of SORLA at certain sites. Preventing that could stop SORLA degradation.” That’s where a rheumatoid arthritis drug called auranofin comes into play. “While it is an arthritis drug, it can also inhibit the PKCι enzyme,” Wang explained. The team conducted tests using Alzheimer’s mouse models and human iPS cells developed into neurons. For the mouse models, they treated the mice with auranofin for eight weeks, resulting in decreased amyloid levels, reduced neuroinflammation and improved cognitive function. Similar results were seen in human cells with increased SORLA levels and decreased amyloid levels. “A good thing about this is, because this is an FDA-approved drug, it’s ready to be tested in Alzheimer’s patients,” Wang said. “People often worry about drug safety because of long-term use in chronic diseases like Alzheimer’s, but, in this case, existing safety data for chronic use gives a good starting point for testing in Alzheimer’s patients. “I hope a drug company can pick that up for a trial with Alzheimer’s patients because we are trying to translate our bench work all the way to the bedside for treatment,” she continued. The study wraps up a five-year National Institute on Aging grant, a collaborative effort between Wang’s lab and the Kai Jiao, MD, PhD, lab in AU’s Center of Biotechnology and Genomic Medicine. Wang’s team is also working on other grant-funded Alzheimer’s-related projects and hopes to continue making advancements toward finding a cure for this debilitating disease. “All of our projects share the goal of finding a better treatment,” Wang said. “Related to this project in particular, we want to know how the SORLA protein works in different types of brain cells, given the brain’s complexity. Then we can determine how to specifically target that protein to develop more effective therapies.” Qin Wang, MD, PhD, researches the neuropharmacology and signaling mechanisms underlying neurological and psychiatric disorders. If you're interested in learning more about her work or booking an interview,  simply click on her icon now to arrange a time to talk.

2 min

Experts in the Media: CBD may help treat and reduce inflammation in Alzheimer's disease

In a recent Medical News Today article, Corrie Pelc reported on a study led by Babak Baban, PhD, in which inhaled CBD (cannabidiol) was tested in a mouse model of Alzheimer’s disease to examine its effects on neuroinflammation. Baban, associate dean for Research with AU's Dental College of Georgia and a professor with appointments in neurology and surgery in the Medical College of Georgia at Augusta University, explained that previous work from his group showed inhaled CBD to be more effective than oral or injected forms for certain neurological conditions, motivating them to explore its potential in Alzheimer’s research. He emphasized that Alzheimer’s is driven by multiple interacting biological processes – not just amyloid plaques – and sees inflammation as a promising new therapeutic target. In the study, inhaled CBD lowered activity in two major immune “alarm” pathways – IDO (indoleamine 2,3-dioxygenase) and cGAS-STING – both implicated in chronic inflammation. By dampening these pathways, CBD reduced levels of inflammatory cytokines and helped restore a more balanced immune environment in the brain. Baban framed this as a shift from symptom treatment to addressing underlying immune dysfunction, and noted that the findings could reorient how Alzheimer’s is approached. At the same time, he stressed that human trials are still needed: his team is preparing translational studies and holds an active Investigational New Drug (IND) application with the FDA for inhaled CBD in neuroinflammatory conditions, with Alzheimer’s disease as a natural next step. Read the full article here: Babak Baban, PhD, is a professor, immunologist and associate dean for research at the Dental College of Georgia at Augusta University where he has served for 13 of his 20 years as a translational and clinical immunologist. View his profile here Looking to know more about this important research or to connect with Babak Baban, PhD? He's available to speak with media – simply click on his icon to arrange an interview today.

View all posts
Powered by